Friday, January 24 2025
Breaking News
* Facebook
* Telegram
* Log In
* Sidebar
* Menu
# SmallCapsDaily
* Search for
1 week ago
## 
Legend Biotech has drawn significant attention recently due to rumors of a potential takeover, with…
3 weeks ago
The energy landscape is undergoing a massive transformation. Traditional gas stations are dying off, while…
4 weeks ago
Boeing has been making headlines with a series of bold moves aimed at restoring its…
The flawless execution of the NFL games on Christmas Day demonstrated the strides Netflix has…
December 24, 2024
The entertainment landscape is buzzing with speculation following recent reports that activist investor Anson Funds…
Logility Supply Chain Solutions has recently attracted significant attention following a call from its shareholder,…
The Dow Jones Industrial Average (DJI) gained some traction back on Wednesday, rising about 0.5%…
U.S. stocks rebounded on Thursday, recovering from the steep losses triggered by a hawkish Federal…
December 20, 2024
Microsoft has secured nearly half a million Nvidia GPUs in 2024 alone, surpassing rivals Google,…
### Trending News
* All
* Biotech
* Breaking
* Business
* Market Movers
* News
  1 week ago 331
  ## 
  Legend Biotech has drawn significant attention recently due to rumors of a potential takeover, with…
  3 weeks ago
  4 weeks ago
  December 24, 2024
US Market
Ticker
Price
Change
%
What’s New
  1 week ago
Load More
##### Free Alerts from Smallcaps Daily.
### Subscribe to our mailing list to get the newest Smallcap alerts as soon as we get them!
###### We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts.
Leave this field empty if you're human:
### Tech
  December 20, 2024 659
  Microsoft has secured nearly half a million Nvidia GPUs in 2024 alone, surpassing rivals Google, Amazon, and Meta given its…
  December 12, 2024 302
  SMCI’s shares surged after an independent investigation found no evidence of fraud and the special committee's recommendation to strengthen governance…
  December 3, 2024 721
  MicroStrategy has been making headlines once again, fueled by its audacious Bitcoin-centric strategy and a meteoric stock price rise of…
### Biotech
  Legend Biotech has drawn significant attention recently due to rumors of a potential takeover, with a 4% surge in its…
  December 4, 2024 557
  On December 3, 2024, the company announced groundbreaking results for its lead drug candidate, JANX007, a tumor-activated T-cell engager targeting…
  August 22, 2024 562
  Maravai LifeSciences has recently caught the attention of Repligen as a potential acquisition target, marking it as a significant player…
### Healthcare
  September 26, 2024 1,476
  Amidst this thriving landscape, SBC Medical Group Holdings (Nasdaq: SBC) has emerged as a leading provider in Japan, offering a…
  September 3, 2024 3,417
  Enter NanoViricides, Inc. (NYSE American: NNVC), a company at the forefront of developing groundbreaking solutions to combat viral infections. With…
  October 26, 2023 857
  Despite economic concerns, the sell-off in big tech, rising interest rates and a looming recession, healthcare stocks are still going…
October 22, 2024
Enter Innovative Beverage Group Limited (Nasdaq: IBG), an undervalued gem in the beverage sector. With a diverse portfolio of premium…
October 7, 2024
Recognizing the shifting global landscape, SMX (Security Matters) (NASDAQ: SMX) is leading the way toward informed intelligence. Through its innovative…
September 26, 2024
Amidst this thriving landscape, SBC Medical Group Holdings (Nasdaq: SBC) has emerged as a leading provider in Japan, offering a…
September 23, 2024
As the opioid crisis escalates and public safety concerns regarding drink spiking grow, Greenlane Holdings, Inc. (NASDAQ: GNLN) is stepping…
  September 10, 2021 6,702
  Cannabidiol, commonly known as CBD, is a naturally occurring chemical compound found in cannabis plants…
  August 3, 2021
* May 14, 2020
  April 20, 2020
  October 3, 2019
* March 25, 2019
Most Viewed
  September 12, 2023
  September 21, 2023
  September 1, 2023
  September 22, 2023
  March 15, 2023
### Trending Tickers
WISH
$9.18
27.72%
* About
SmallCapsDaily.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, in-depth broadcasts on Stock News, Market Analysis and Company Interviews.
SmallCapsDaily.com also provides financial news PR marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
© Copyright 2025, All Rights Reserved  |   
Close
Search for:
Popular Posts
  November 24, 2024
  November 25, 2024
Recent Comments
Newsletter
Log In
 Remember me
# 5 of Today’s Biggest Marijuana Stock Gainers – December 27, 2018
Send an email
December 27, 2018 817  1 minute read
[ad\_1]
Out of over 200+ marijuana shares, listed below are 5 of the most important marijuana stock winners in buying and selling as we speak on Thursday, December 27, 2018 together with 22nd Century Group Inc (NYSE:XXII) and extra…
### ****
Today, shares of  closed the buying and selling day up at $2.45 per share. When in comparison with the earlier shut of $2.36 per share, as we speak’s improve of $0.09 per share represents an approximate 3.81% bump in value for shares of XXII.
Today, shares of  closed the buying and selling day up at $0.061 per share. When in comparison with the earlier shut of $0.0565 per share, as we speak’s improve of $0.0045 per share represents an approximate 7.96% bump in value for shares of BLEVF.
Today, shares of  closed the buying and selling day up at $0.08 per share. When in comparison with the earlier shut of $0.07 per share, as we speak’s improve of $0.01 per share represents an approximate 14.29% bump in value for shares of GLDFF.
Today, shares of  closed the buying and selling day up at $4.39 per share. When in comparison with the earlier shut of $4.12 per share, as we speak’s improve of $0.27 per share represents an approximate 6.55% bump in value for shares of ORHOF.
Today, shares of  closed the buying and selling day up at $0.78 per share. When in comparison with the earlier shut of $0.74 per share, as we speak’s improve of $0.04 per share represents an approximate 5.41% bump in value for shares of WDDMF.
*Be positive to  so that you by no means miss an necessary replace.*
Get Real-Time Updates from The Daily Marijuana Observer
[ad\_2]
Show More
 Share
Share via Email
### Related Articles
### 
September 10, 2021
August 3, 2021
May 14, 2020
Check Also
  May 14, 2020
Leave this field empty if you're human: 
  December 14, 2020
  March 10, 2022
Recent News
Viber
xml version="1.0" encoding="UTF-8"?
Comments for Smallcaps Daily
Smallcap Stock News Daily
Wed, 15 Jan 2025 20:28:49 +0000
hourly
1
# Legend Biotech: Why The Recent Takeover Speculation Is Worth Your Attention!
1 week ago 331  3 minutes read
!
Legend Biotech Corporation (NASDAQ:LEGN) has been at the forefront of revolutionary cancer treatment with its CAR-T therapy, CARVYKTI. The company has drawn significant attention recently due to rumors of a potential takeover, with a 4% surge in its stock price amidst the speculation. While the identity of the interested party remains unclear, industry whispers hint at potential interest from major pharmaceutical players. This buzz comes in the wake of Legend Biotech’s presentation at the 43rd Annual J.P. Morgan Healthcare Conference, where the company highlighted its robust growth trajectory, innovative pipeline, and ongoing partnerships. As the world’s largest stand-alone cell therapy company with a stronghold in CAR-T therapies, Legend Biotech’s appeal to acquirers is unmistakable. Let us take a closer look and explore the biggest factors that make Legend Biotech a prime acquisition target.
### **CARVYKTI’s Market Leadership & Expanding Reach**
CARVYKTI has established itself as the most successful CAR-T launch in history, generating $286 million in global sales in Q3 2024 and showcasing a remarkable 88% year-over-year growth. This FDA-approved therapy for multiple myeloma provides significant survival benefits over standard treatments, making it a cornerstone therapy in the oncology space. The therapy's ability to penetrate both inpatient and outpatient settings has further enhanced its marketability, with outpatient usage surging from 30% to 48% over the past year. Legend Biotech's aggressive manufacturing expansion, including facilities in New Jersey and Belgium, aims to double its production capacity to meet growing global demand. Its partnership with Johnson & Johnson (J&J) has fortified its position in the oncology market, leveraging J&J's leadership in multiple myeloma to deepen CARVYKTI’s penetration in the second-line setting. This unparalleled success and scalability make Legend Biotech a lucrative target for pharmaceutical companies seeking to bolster their oncology portfolios.
### **Pioneering Innovation In CAR-T & Beyond**
Legend Biotech’s R&D pipeline extends beyond CARVYKTI, targeting various cancers and autoimmune diseases through next-generation CAR-T therapies. The company’s partnership with Novartis to develop DLL3-targeted CAR-T therapies for small cell lung cancer has already yielded significant milestones, including a $100 million upfront payment and the potential for $1 billion in future milestone payments. The company’s advanced armoring strategies and antibody engineering capabilities ensure that its therapies maintain high efficacy and safety profiles. Additionally, Legend Biotech is actively exploring allogeneic therapies and in vivo CAR-T solutions, demonstrating its commitment to pioneering treatments that address unmet medical needs. With its robust pipeline and strategic partnerships, Legend Biotech presents a compelling opportunity for acquirers aiming to dominate the burgeoning cell therapy market.
### **Strong Financial Performance & Operational Efficiency**
Legend Biotech’s financial trajectory underscores its operational strength and market potential. Revenues have tripled since 2022, reaching nearly $950 million in 2024, with projections to surpass $1.9 billion in 2025. The company’s manufacturing facilities, including the world’s largest CAR-T manufacturing site in New Jersey, operate at near-full capacity, with plans to scale production to 10,000 doses annually by year-end. This operational efficiency not only enhances Legend Biotech’s profitability but also positions it as a reliable partner for global supply chains. The company’s ability to reduce out-of-spec rates and optimize production aligns with the industry’s emphasis on quality and scalability. These financial and operational metrics make Legend Biotech an attractive acquisition for companies looking to enhance their earnings and operational footprint in the cell therapy domain.
### **Strategic Global Partnerships & Market Expansion**
Legend Biotech’s strategic collaborations, particularly with J&J and Novartis, amplify its global footprint and access to critical resources. These partnerships not only provide financial backing but also ensure the rapid commercialization of its therapies in key markets. For instance, its partnership with Novartis integrates T-Charge manufacturing technology, enhancing production efficiency and addressing the urgent needs of small cell lung cancer patients. Additionally, Legend Biotech is actively expanding its market presence beyond the U.S., with plans to launch in 15 new markets, including Europe and Japan, in 2025. The company’s ability to navigate regulatory landscapes and secure approvals in multiple jurisdictions further strengthens its appeal to acquirers with global ambitions. These strategic partnerships and market expansions underline Legend Biotech’s potential to deliver sustainable growth and innovation in the biopharmaceutical sector.
### **Final Thoughts**
*Source: Yahoo Finance*
Legend Biotech’s stock performance has been rather poor in 2024 but its valuation levels look far more realistic now from an acquisition standpoint. The company, which was trading at an LTM EV/ Revenue of 42.15x in March 2023 is now down to 9.49x, a far more reasonable level at which it can actually get acquired. We believe that Legend Biotech stands out as a formidable player in the cell therapy landscape, combining market leadership, innovative R&D, operational efficiency, and strategic collaborations. These attributes not only position the company as a trailblazer in oncology but also as an enticing acquisition target for major pharmaceutical companies looking to consolidate their presence in the rapidly growing cell therapy market. However, investors should approach the speculation with caution, weighing both the opportunities and risks associated with the company’s ambitious growth plans and competitive dynamics. As the rumor mill churns, one thing is clear: Legend Biotech’s journey is one to watch closely.